234 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
IONS Ionis Pharmaceuticals, Inc. $48.21 $6.62B N/A
Article Searches
4 Scorching Hot Momentum Stocks to Beat the Market http://www.zacks.com/stock/news/280858/4-scorching-hot-momentum-stocks-to-beat-the-market?cid=CS-ZC-FT-280858 Oct 30, 2017 - This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.
Should You Buy Ionis (IONS) Ahead of Earnings? http://www.zacks.com/stock/news/281823/should-you-buy-ionis-ions-ahead-of-earnings?cid=CS-ZC--281823 Nov 06, 2017 - Ionis Pharmaceuticals, Inc. (IONS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Ionis (IONS) Beats on Q3 Earnings, Revenues Miss http://www.zacks.com/stock/news/282013/ionis-ions-beats-on-q3-earnings-revenues-miss?cid=CS-ZC--282013 Nov 07, 2017 - Ionis Pharmaceutical (IONS) reported mixed quarter with earnings beating estimates while revenues missing it.
Tesla (TSLA) Builds Largest Lithium-Ion Battery in Australia http://www.zacks.com/stock/news/284042/tesla-tsla-builds-largest-lithium-ion-battery-in-australia?cid=CS-ZC-FT-284042 Nov 27, 2017 - Tesla (TSLA) completes installation of the lithium-ion battery in South Australia within 55 days of signing the grid connection deal.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy http://www.zacks.com/stock/news/286464/biotech-stock-roundup-label-expansion-for-exelixiss-cabometyx-fda-nod-for-sparks-gene-therapy?cid=CS-ZC-FT-286464 Dec 20, 2017 - A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Biogen Halts Tysabri Development in Stroke as Study Fails http://www.zacks.com/stock/news/291869/biogen-halts-tysabri-development-in-stroke-as-study-fails?cid=CS-ZC-FT-291869 Feb 08, 2018 - Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
What's in the Cards for Ionis (IONS) This Earnings Season? http://www.zacks.com/stock/news/293248/whats-in-the-cards-for-ionis-ions-this-earnings-season?cid=CS-ZC-FT-293248 Feb 22, 2018 - Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm http://www.zacks.com/stock/news/293455/pharma-stock-roundup-azns-imfinzi-gets-2nd-fda-nod-mrk-to-buy-australian-firm?cid=CS-ZC-FT-293455 Feb 23, 2018 - Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III http://www.zacks.com/stock/news/297688/pfizers-rare-disease-candidate-meets-endpoint-in-phase-iii?cid=CS-ZC-FT-297688 Apr 02, 2018 - Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Alnylam Falls on Pfizer's Rare Disease Drug Success http://www.zacks.com/stock/news/297723/alnylam-falls-on-pfizers-rare-disease-drug-success?cid=CS-ZC-FT-297723 Apr 02, 2018 - Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

Pages: 1...1718192021222324

<<<Page 22>